How will new and future therapies change our treatment of IBD?

Zundler S, Neurath M (2016)

Publication Type: Journal article, Editorial

Publication year: 2016

Journal

Expert Review of Clinical Immunology Expert Reviews (formerly Future Drugs)

Book Volume: 12

Pages Range: 233-6

Journal Issue: 3

DOI: 10.1586/1744666X.2016.1112271

Abstract

Fundamental insights into the pathogenesis of inflammatory bowel diseases (IBD) have led to the development of new therapies and lots of experimental compounds in the pipeline. Our treatment of IBD is therefore constantly evolving. In this editorial, we postulate that bi- or even polyspecific therapy will be an important mainstay of future IBD treatment. Moreover, we highlight some promising new therapeutic concepts currently under investigation and point at the outstanding and growing importance of personalized medicine to assign drugs from the increasing pool of options to the individual patient.

Authors with CRIS profile

Sebastian Zundler Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology Markus Neurath Lehrstuhl für Innere Medizin I

How to cite

APA:

Zundler, S., & Neurath, M. (2016). How will new and future therapies change our treatment of IBD? Expert Review of Clinical Immunology, 12(3), 233-6. https://doi.org/10.1586/1744666X.2016.1112271

MLA:

Zundler, Sebastian, and Markus Neurath. "How will new and future therapies change our treatment of IBD?" Expert Review of Clinical Immunology 12.3 (2016): 233-6.

BibTeX: Download